Alan Smith

Cell and Gene Therapy Advisor

Dr. Smith has over 40 years of experience in the cell therapy and gene therapy field with experience in a wide variety of cell types and viral vector platforms. He has extensive experience in research, process development, GMP manufacturing, quality control, quality assurance, analytical and assay development, GMP facilities design, construction and operation and GMP supply chain and procurement.

He most recently served as Chief Technology Officer of Ambys Medicines, Inc. Prior to his time at Ambys Medicines, Dr. Smith served as Chief Technology Officer at Akouos, Inc., a gene therapy company focused on cures for genetic hearing defects (acquired by Lilly), and was Executive Vice President, Technical Operations at Bellicum Pharmaceuticals, Inc. Dr. Smith previously served as Vice President of Research & Development and Cellular Therapeutics for LifeNet Health, Inc. and its wholly owned subsidiary, The Institute of Regenerative Medicine.

He also operated a successful consulting company serving the cell and gene therapy field for a number of years. Earlier in his career, Dr. Smith served as President and CEO of Cognate BioServices (now part of Charles River Laboratories); Chief Operating Officer and Senior Vice President of R&D for Osiris Therapeutics; led the R&D functions for Aastrom Biosciences and Genetic Sciences; and served as Director of Cell Separations R&D at Baxter Healthcare and Director of Biochemistry at HyClone Laboratories (now part of Thermo Fisher).

Over the course of his career, he has been a material contributor to more than 25 successful regulatory applications for human cell therapy clinical trials and medical devices. Dr. Smith has previously held adjunct professor appointments at Eastern Virginia Medical School, California State University, Long Beach and Utah State University and has served in a number of academic advisory panel positions. He holds a B.S. in Chemistry from Southern Utah University and a Ph.D. in biochemistry from Utah State University.